Search clinical trials for: Small molecule kinase inhibitor

Total 75620 results

Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Hunan Province Tumor Hospital

Recruiting

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Small-cell Lung Cancer

China
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Stanford University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Nasopharyngeal Cancer | Epstein-Barr Virus Related Carcinoma

United States
National University Hospital, Singapore
Boehringer Ingelheim

Recruiting

Observational Study of Afatinib 30 mg Daily

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor Mutation

Singapore
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi Sarcoma | Viral Associated Malignancies | EBV/KSHV-associated Lymphomas

United States
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Deciphera Pharmaceuticals LLC

Recruiting

A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Non-Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor

United States
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Medical University Innsbruck
Merck Sharp & Dohme LLC

Recruiting

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (INNWOP1)

Non Small Cell Lung Cancer

Austria
NKMAX Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment (SNK_ASTER)

Non-small Cell Lung Cancer

Korea, Republic of
Merus N.V.

Recruiting

A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Non-Small Cell Lung Cancer Metastatic

United States, Spain, France, Italy, Netherlands, Belgium, Korea, Republic of, Germany, Singapore
Chipscreen Biosciences, Ltd.

Recruiting

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Small Cell Lung Cancer

China
Yonsei University

Recruiting

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Non Small Cell Lung Cancer

Korea, Republic of
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
Fondazione Ricerca Traslazionale

Recruiting

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)

NSCLC

Italy
National Cancer Institute (NCI)

Recruiting

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

SCLC | Advanced Solid Tumor | Small Cell Cancer | High Grade Neuroendocrine Cancers

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8

United States
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Spain, Israel, Japan, France
Instituto Oncológico Dr Rosell
Turning Point Therapeutics, Inc.

Recruiting

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

Nsclc

Spain
Shanghai Chest Hospital

Recruiting

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib (AUTOMAN)

Metastatic Cancer | Adenocarcinoma of Lung | Non-Small Cell Lung Cancer With EGFR Mutation | Locally Advanced Solid Tumor

China
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (FLAME)

Non Small Cell Lung Cancer

China
Emory University
National Cancer Institute (NCI)

Recruiting

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Washington University School of Medicine
Apollomics Inc.

Recruiting

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Metastatic Non Small Cell Lung Cancer

United States
Li Zhang, MD

Not yet recruiting

Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations (TOP)

Non-small Cell Carcinoma | EGFR Gene Mutation

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Small-cell Lung Cancer
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Taiwan, Japan
Junling Li

Recruiting

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Advanced Non Squamous NSCLC

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
Hoffmann-La Roche

Recruiting

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Carcinoma, Non-Small-Cell Lung

China, France, Croatia, Brazil, Greece, Italy, Mexico, Spain, India, Netherlands, Romania, Sweden, Thailand, Lebanon, Turkey, Germany, Slovakia, Jordan, Russian Federation
Massachusetts General Hospital
Genentech, Inc.

Recruiting

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Shanghai Cancer Hospital, China

Recruiting

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Lung Cancer Stage IV

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

NSCLC
University of Texas Southwestern Medical Center

Recruiting

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Advanced Squamous Non Small Cell Lung Cancer

United States
Genprex, Inc.

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1)

Carcinoma, Non-Small Cell Lung

United States
Fifth Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (Neoafa)

Chemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
Jun Zhang, MD, PhD
University of Iowa; University of Kentucky

Recruiting

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)

NSCLC Stage IV | NSCLC Stage IIIB

United States
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Peking Union Medical College Hospital

Recruiting

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Small Cell Lung Carcinoma

China
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors

United States, Korea, Republic of, Spain, United Kingdom, Brazil, Israel, New Zealand, Netherlands, Canada, Australia, Switzerland, Belgium, Italy, Norway, Poland, Hungary, Kenya, Russian Federation, Germany
Memorial Sloan Kettering Cancer Center
AstraZeneca; Guardant Health, Inc.

Recruiting

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Metastatic Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Malignant Solid Neoplasm | Melanoma | Colitis | Lung Non-Small Cell Carcinoma | Malignant Genitourinary System Neoplasm

United States
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China

Search clinical trials for: Small molecule kinase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations